The nasal polyps market reached a value of USD 71.6 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 128.7 Million by 2035, exhibiting a growth rate (CAGR) of 5.60% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 71.6 Million
|
Market Forecast in 2035
|
USD 128.7 Million
|
Market Growth Rate (2025-2035)
|
5.60% |
The nasal polyps market has been comprehensively analyzed in IMARC's new report titled "Nasal Polyps Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Nasal polyps refer to a medical condition in which there are soft, painless growths on the lining of the nasal passage or sinuses. They are noncancerous and often occur in the area where the sinuses open into the nasal cavity. Nasal polyps can be single or multiple and vary in size from small to large. The common symptoms of this ailment include a runny nose, persistent stuffiness, postnasal drip, decreased or absent sense of smell, facial pain, frequent nosebleeds, headache, snoring, pain in the upper teeth, a sense of pressure over the forehead and face, etc. The diagnosis of the illness is typically based on the patient’s medical history, clinical features, and a general physical test. Nasal endoscopy is further recommended in patients for a detailed examination of the nose and sinuses. The healthcare professional may also perform imaging studies, such as a computerized tomography (CT) scan, to evaluate the location and size of polyps in deeper areas of the sinuses and rule out other possible blockages in the nasal cavity.
To get more information on this market, Request Sample
The rising cases of allergies or infections, which trigger long-term inflammation and irritation in the nasal passage, are primarily driving the nasal polyps market. Moreover, the increasing incidence of genetic mutations associated with immune system functioning that result in the formation of abnormally thick, sticky mucus from the nasal and sinus linings is also bolstering the market growth. In addition to this, the widespread adoption of intranasal corticosteroid injections, like fluticasone, over conventional oral drugs on account of their improved efficacy profiles and lower risk of systemic side effects, is acting as another significant growth-inducing factor. Furthermore, the escalating demand for image guided endoscopic sinus surgery, which helps to improve precision, reduce complications, and enhance surgical outcomes in patients, is also creating a positive outlook for the market. Additionally, the rising popularity of biological drugs for treating the ailment, as they work by targeting specific proteins or cells to reduce swelling and irritation in the nasal passage, is expected to drive the nasal polyps’ market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Nasal Polyps market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Nasal Polyps and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Nasal Polyps market in any manner.
Dupixent is a prescription therapy used with additional medicines to maintain the treatment of CRSwNP in individuals whose condition is not under control. It works by blocking two key sources of type 2 inflammation, shrinking nasal polyps, and minimizing the need for surgery.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current nasal polyps marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Dupixent (Dupilumab) | Sanofi/Regeneron Pharmaceuticals, Inc. |
Nucala (Mepolizumab) | GlaxoSmithKline |
Xolair (Omalizumab) | Genentech, Inc./Novartis AG |
Xhance (Fluticasone propionate) | Optinose, Inc. |
Itepekimab | Sanofi |
Verekitug (UPB-101) | Upstream Bio, Inc. |
Brensocatib | Insmed Incorporated |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Nasal Polyps: Current Treatment Scenario, Marketed Drugs and Emerging Therapies